Empliciti® (elotuzumab) – New indication
November 6, 2018 - Bristol-Myers Squibb announced the FDA approval of Empliciti (elotuzumab), in combination with Pomalyst® (pomalidomide) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including Revlimid® (lenalidomide) and a proteasome inhibitor.
Top